EP 3661921 B1 20231018 - SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
Title (en)
SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
Title (de)
SELEKTIVE HEMMER VON NLRP3-INFLAMMASOM
Title (fr)
INHIBITEURS SÉLECTIFS DE L'INFLAMMASOME NLRP3
Publication
Application
Priority
- GB 201712282 A 20170731
- EP 2018070799 W 20180731
Abstract (en)
[origin: WO2019025467A1] The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
IPC 8 full level
C07D 307/87 (2006.01); A61K 31/343 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4965 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); C07D 231/12 (2006.01); C07D 233/56 (2006.01); C07D 237/08 (2006.01); C07D 239/26 (2006.01); C07D 241/12 (2006.01); C07D 249/08 (2006.01)
CPC (source: EA EP IL KR US)
A61K 31/27 (2013.01 - KR); A61K 31/325 (2013.01 - IL); A61K 31/343 (2013.01 - EA EP KR); A61K 31/415 (2013.01 - EA EP KR); A61K 31/4164 (2013.01 - EA EP KR); A61K 31/4965 (2013.01 - EA EP KR); A61P 25/00 (2018.01 - IL KR); A61P 29/00 (2018.01 - EA EP IL KR); A61P 35/00 (2018.01 - IL KR); A61P 37/00 (2018.01 - EA EP KR); A61P 37/06 (2018.01 - IL US); C07C 45/68 (2013.01 - US); C07C 201/14 (2013.01 - US); C07C 209/36 (2013.01 - US); C07C 263/10 (2013.01 - US); C07C 271/28 (2013.01 - IL US); C07C 271/30 (2013.01 - IL US); C07D 213/55 (2013.01 - US); C07D 231/12 (2013.01 - EA EP IL KR US); C07D 231/14 (2013.01 - US); C07D 231/16 (2013.01 - IL); C07D 233/56 (2013.01 - EA EP KR); C07D 233/60 (2013.01 - IL US); C07D 237/08 (2013.01 - EA EP IL KR US); C07D 239/26 (2013.01 - EA EP IL KR US); C07D 241/12 (2013.01 - EA EP IL KR US); C07D 241/24 (2013.01 - US); C07D 249/08 (2013.01 - EA EP IL KR US); C07D 307/79 (2013.01 - IL US); C07D 307/87 (2013.01 - EA EP KR); C07D 309/12 (2013.01 - US); C07D 409/12 (2013.01 - KR US); C07D 491/04 (2013.01 - EP); C07D 493/04 (2013.01 - KR US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2019025467 A1 20190207; AU 2018311198 A1 20200206; AU 2018311198 B2 20230202; BR 112020001713 A2 20200721; CA 3070515 A1 20190207; CN 111356680 A 20200630; CN 111356680 B 20231128; DK 3661921 T3 20240108; EA 202090419 A1 20200619; EP 3661921 A1 20200610; EP 3661921 B1 20231018; ES 2968669 T3 20240513; FI 3661921 T3 20240103; GB 201712282 D0 20170913; HR P20231690 T1 20240315; HU E065337 T2 20240528; IL 272052 A 20200331; IL 272052 B1 20230701; IL 272052 B2 20231101; JP 2020529405 A 20201008; JP 2023116627 A 20230822; JP 7357602 B2 20231006; KR 20200115448 A 20201007; LT 3661921 T 20240212; MX 2020001218 A 20200324; PL 3661921 T3 20240422; PT 3661921 T 20240108; RS 65100 B1 20240229; SG 11202000325U A 20200227; SI 3661921 T1 20240329; TW 201910306 A 20190316; TW I810198 B 20230801; US 2021087147 A1 20210325
DOCDB simple family (application)
EP 2018070799 W 20180731; AU 2018311198 A 20180731; BR 112020001713 A 20180731; CA 3070515 A 20180731; CN 201880063698 A 20180731; DK 18755728 T 20180731; EA 202090419 A 20180731; EP 18755728 A 20180731; ES 18755728 T 20180731; FI 18755728 T 20180731; GB 201712282 A 20170731; HR P20231690 T 20180731; HU E18755728 A 20180731; IL 27205220 A 20200115; JP 2020505150 A 20180731; JP 2023094466 A 20230608; KR 20207005819 A 20180731; LT EP2018070799 T 20180731; MX 2020001218 A 20180731; PL 18755728 T 20180731; PT 18755728 T 20180731; RS P20240024 A 20180731; SG 11202000325U A 20180731; SI 201831042 T 20180731; TW 107126572 A 20180731; US 201816635374 A 20180731